Prevalence of XXXX in Alaska Natives.

@entity2835 @entity1 @entity82 @entity1087 @entity409 @entity991 @entity1448 @entity99 @entity792 @entity775
OBJECTIVE: There is limited information on the prevalence of @entity409 in nonwhite populations. We conducted a population-based study on the prevalence of @entity409 in Alaska natives. METHODS: Clinical records from 1984 to July, 2000 were reviewed to identify Alaska natives with @entity775 ( @entity775 ), @entity2835 ( @entity2835 ), @entity991 , @entity792 , and overlap syndromes of two of the above. @entity775 was defined as definite or probable, based on criteria established by the International @entity775 Group. The diagnosis of @entity2835 was based on a positive antimitochondrial antibody of > or = 1: 40, biochemical evidence of @entity1448 , and compatible liver biopsy. @entity792 was defined as @entity2835 but without a positive antimitochondrial antibody. @entity991 was diagnosed on the basis of cholangiogram. RESULTS: Seventy-seven @entity1 with possible @entity409 were identified. Of these, 42 had definite and seven probable @entity775 . At presentation, 34.7% of @entity1 with @entity775 presented with acute @entity99 , and 65.3% were asymptomatic. @entity1 presenting with mild or no symptoms were more likely to have moderate to severe @entity82 on liver biopsy than those presenting with @entity1087 . Eighteen @entity1 were diagnosed with @entity2835 , five with @entity792 , five with overlap syndrome, and none with @entity991 . The combined point prevalence of @entity775 Alaska natives was 42.9/100,000 (95% CI = 31-57.7). The prevalence of @entity2835 was 16/100,000 (95% CI = 12.9-25.4). CONCLUSIONS: This population-based study demonstrates that the prevalence rates of @entity775 and @entity2835 in Alaska natives are comparable with reported rates in other populations.
